An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

Abstract evidence1 comparisonAutomated source matching · not expert reviewed

Partial coverage · gaps are marked inside each comparison

Some results can be visualized; unassessed context remains visible.

Choose a comparison

1 comparisons · Each follows its own evidence.

What happened? What does this reported comparison show?

One comparison, followed all the way through

This comparison is not yet interpretable.

Its exact outcome or compared groups still need to be established from the source.

Follow the study

The study design is not ready to draw

Comparison-level assignment evidence has not been extracted.

Open the paper record

Relative comparison

hazard ratio

← Smaller hazard ratioLarger hazard ratio →

Reported statistic · comparison details unresolved0.63× 0.46 to 0.87×

0.5×No difference

Reported estimate95% confidence intervalEqual steps show equal ratios

The reported number can be shown, but its exact outcome or compared groups are unresolved. Its direction cannot be interpreted here.

A hazard ratio compares the rate of events among those still at risk over follow-up. It is not a ratio of the percentages in a people picture. The confidence interval describes statistical uncertainty under the model, not every possible source of error.

Paper abstract · Abstract

This picture is incomplete

The outcome name has not been resolved from the source.
The comparison labels have not both been resolved from the source.
The outcome and group labels are not all tied to this result quotation.

Paper abstract · Abstract

Read the source context

Comparison details unresolved.

The exact outcome or compared groups are not yet fully established. The source needs interpretation before this number can support a conclusion.

Read reported excerpt

METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib ( RESULTS: After matching selected covariates, statistically significant differences were observed with zanubrutinib versus ibrutinib for progression-free survival (hazard ratio [HR] = 0.63; 95% confidence interval [CI] 0.46-0.87, CONCLUSION: These MAIC analyses demonstrate that zanubrutinib may be more effective than ibrutinib at delaying disease progression and death in R/R MCL.

Paper abstract · Abstract

Automated source matching has not been reviewed by a scientific expert. This comparison's assignment method is not established.

Keep the limits in view

Study-specific limitations have not been assessed

An empty limitations list does not mean the study has no limitations.

Paper abstract · Abstract

Inspect the source trail for this comparison

Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
METHODS: Following a systematic literature review, individual patient data from trials of zanubrutinib ( RESULTS: After matching selected covariates, statistically significant differences were observed with zanubrutinib versus ibrutinib for progression-free survival (hazard ratio [HR] = 0.63; 95% confidence interval [CI] 0.46-0.87, CONCLUSION: These MAIC analyses demonstrate that zanubrutinib may be more effective than ibrutinib at delaying disease progression and death in R/R MCL.